Breast Cancer Coverage from Every Angle

Cristina Saura, MD, on Breast Cancer: Results from the LORELEI Trial

Posted: Tuesday, September 12, 2017

Cristina Saura, MD, of Vall d’Hebron Institute of Oncology, discusses phase II study findings on neoadjuvant letrozole plus taselisib vs letrozole plus placebo in postmenopausal patients with ER+/HER2– early breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.